Bone Biologics Corp
Close on Oct 19, 2026
- Market cap
- $737.57K
- P/E (TTM)
- –
- Dividend yield
- –
About Bone Biologics
Orthopedic, Prosthetic & Surgical Appliances & Supplies, SIC 3842
Bone Biologics Corporation is a clinical-stage medical device company focused on bone regeneration in spinal fusion surgery. Its core technology platform utilizes NELL-1, a proprietary recombinant human protein growth factor designed to regulate skeletal tissue formation and stem cell differentiation. The company's lead product candidate is NB1, a combination medical device that incorporates the NELL-1 recombinant protein with demineralized bone matrix (DBM). The product is designed to promote targeted bone growth during spinal fusion procedures, initially targeting adult patients with degenerative disc disease undergoing transforaminal lumbar interbody fusion. Beyond spinal applications, the company holds rights to develop the platform for osteoporosis and trauma treatments.
The company operates primarily through research, development, and clinical evaluation programs. Its pilot clinical study for the NB1 bone graft device is conducted across multiple centers in Australia, following preclinical testing in sheep models. Bone Biologics Corporation maintains its principal executive offices in Burlington, Massachusetts.
Summary of the business section of Bone Biologics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Bone Biologics Corp
- Founded
- 2004
- Headquarters
- Burlington, MA
- Address
- 2 Burlington Woods Drive,, Suite 100, 01803
- Phone
- (781) 552-4452
- Industry
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Weinberg & Company, P.A, Los Angeles, California
Stock & identifiers
- Ticker
- BBLG
- Other tickers
- BBLGW
- Exchange
- Nasdaq
- Shares outstanding
- 3M, Aug 14, 2026
- Public float
- $7.23M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-6 reverse, Jun 10, 2025; 1-for-8 reverse, Feb 21, 2024; 1-for-8 reverse, Dec 20, 2023; 1-for-30 reverse, Aug 14, 2023; 1-for-30 reverse, Jun 7, 2023; 1-for-2.5 reverse, Nov 15, 2021; 1-for-10 reverse, Aug 14, 2018
- SEC CIK
- 1419554
- CUSIP
- 098070600
- ISIN
- US0980706008
- EIN
- 42-1743430
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Jeff Frelick | Chief Executive Officer | 360 |
| Deina H. Walsh | Chief Financial Officer | 313 |
| Robert E. Gagnon | Director | 0 |
| Phillip Terry Meikle II | Director | – |
| Bruce Stroever | Director | 0 |
| Siddhesh Rajendra Angle | Director | – |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Mr. Frelick | $426.27K | $430.79K | $263.14K | $0 | – |
| FY2024 Mr. Frelick | $384.90K | $405.71K | $242.45K | $0 | – |
| FY2024 Non Peo Neo | $242.45K | $252.86K | $242.45K | $0 | – |
| FY2024 Peo | $384.90K | $405.71K | $242.45K | $0 | – |
| FY2023 Mr. Frelick | $376.60K | $332.97K | $238.30K | $0 | – |
| FY2022 Mr. Frelick | $414.72K | $406.75K | $250.46K | $4 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Corporate history
Events identified from SEC filings